Kadar Cyfra 21-1 dan CD8 pada Pasien Kanker Paru Bukan Sel Kecil (KPKBSK) yang Dilakukan Kemoterapi di Kota Medan

Abstract

Background: Lung cancer is the leading cause of cancer incidence and death worldwide. Lung cancer is divided based on cell of origin into Small Cell Carcinoma Lung Cancer (SCLC) and Non-Small Cell Carcinoma Lung Cancer (NSCLC). Based on the predominance of advanced stage diagnosis, it would be assumed that chemotherapy would be the mainstay of treatment for non-small cell carcinoma lung cancer. Cytokeratins are epithelial markers whose expression is not lost during malignant transformation. CYFRA 21-1 is a serum-soluble fragment of cytokeratin-19. CYFRA 21-1 has been used as a tumor marker for Non-Small Cell Lung Cancer. Cytotoxic T cells expressing cell surface CD8 are the most powerful effectors in anticancer immune responses and form the backbone of today's successful cancer immunotherapies. Objective: To determine the value of CYFRA 21-1 and CD8 levels in patients with NSCLC. Methods: This study is an observational study with blood collection in patients with NSCLC. Results: Of the 20 patients studied, all were male. The largest type of KPKBSK was adenocarcinoma with a percentage of 60%. For CD8, the minimum value of CD8 was 1.5886 and the maximum value of CD8 was 8.5930, with a mean of 3.551030. The minimum value of CYFRA 21-1 was 0.3258 and the maximum value of CYFRA 21-1 was 61.7025, with a mean of 17.202430.